查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1884070

甲型肝炎疫苗市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察與預測（2024-2032 年）

Hepatitis A Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 196 Pages | 商品交期: 請詢問到貨日

價格

甲型肝炎疫苗市場成長驅動因素

由於甲型肝炎疾病流行率上升、疫苗接種計劃擴大以及政府主導的旨在預防甲型肝炎感染的舉措增加，全球甲型肝炎疫苗市場正經歷顯著增長。根據本報告，預計該市場規模將在 2024 年達到 12.4 億美元，並在 2025 年增長至 12.6 億美元。預計到 2032 年，該市場規模將顯著成長至 25.7 億美元，在預測期內實現 10.7% 的強勁複合年增長率。北美地區憑藉其先進的醫療保健體系和廣泛的疫苗接種覆蓋率，在 2024 年保持了其領先地位，市場佔有率達到 50%。

甲型肝炎是一種病毒性肝臟感染，主要透過受污染的食物和水或密切接觸傳播。症狀包括發燒、噁心、腹部不適，嚴重時可出現黃疸和急性肝衰竭。由於衛生條件差、個人衛生習慣不良以及清潔用水匱乏，這種感染在低收入和中等收入地區尤其常見。由於接種疫苗是最有效的預防措施，全球對甲型肝炎疫苗的需求持續成長。葛蘭素史克（GSK plc）、賽諾菲（Sanofi）、默克（Merck & Co.）和科興生物（Sinovac）等主要公司提供全球認可的疫苗，並致力於提高疫苗接種率。

市場驅動因素

甲型肝炎病例呈上升趨勢

全球甲型肝炎病例的不斷增加推動了疫苗接種工作。衛生條件差、水源受污染和個人衛生習慣不良仍是主要的風險因素。例如，烏茲別克在2024年的前兩個月報告了9507例兒童甲型肝炎感染病例，凸顯了在高風險地區開展疫苗接種計劃的緊迫性。

各國政府加強疫苗接種計畫

世界各國政府正在擴大國家疫苗接種計劃，以預防疫情爆發並最大限度地降低醫療成本。在歐盟/歐洲經濟區，2022年報告了4548例病例，促使當局加強疫苗接種策略。

市場限制

疫苗價格高且取得途徑有限

甲型肝炎疫苗的生產需要冷鏈物流和嚴格的監管合規，這推高了整體成本。這限制了低收入國家的取得途徑。在墨西哥，單劑疫苗的價格為935.7美元，而完成免疫需要兩劑，這使得許多人難以負擔疫苗。疫苗價格可承受性方面的差距持續阻礙著全球根除甲型肝炎的努力。

市場機會

新興市場的本土疫苗研發

印度和中國等國家正在投資本土疫苗研發，以減少對進口的依賴。 2024年1月，印度免疫公司（Indo Immunologicals）推出了印度首款國產甲型肝炎疫苗Havisure，顯著提高了疫苗的可及性和可負擔性。預計到2032年，此類本土創新將創造巨大的市場機會。

市場挑戰

冷鏈效率低

甲型肝炎疫苗必須儲存在2°C至8°C之間。許多低收入地區缺乏足夠的冷鏈基礎設施，促使疫苗浪費和免疫接種率低。這些限制仍然是市場擴張的主要障礙。

市場趨勢

旅行疫苗需求成長

隨著全球旅行的增加，旅行者對甲型肝炎疫苗的需求顯著增長。高收入國家的旅行診所和藥房報告稱，他們會主動為前往甲型肝炎流行地區的旅客接種疫苗。例如，韓國強烈建議在前往風險地區之前至少接種一劑疫苗。

細分市場概覽

按類型

由於全球批准和廣泛供應，滅活疫苗細分市場在2024年佔主導地位。 2023年，中國生物技術有限公司（SINOVAC）的滅活疫苗 "Healive" 在吉爾吉斯斯坦獲得監管部門批准。雖然活疫苗有效，但其市場仍集中在印度和中國。

依年齡組

由於成熟的疫苗接種方案，兒童區隔市場引領市場。美國疾病管制與預防中心 (CDC) 建議所有 12 至 23 個月大的嬰兒進行常規疫苗接種。

依劑型劃分

由於易於接種，液體疫苗（例如默克公司的 Vaqta 和葛蘭素史克公司的 Havrix）佔了大部分市場佔有率。凍乾粉劑疫苗因其更長的保存期限和儲存優勢仍然十分重要。

依通路劃分

在 2024 年，政府採購機構在大規模採購項目的推動下，佔了市場主導地位。 2025 年，全球疫苗免疫聯盟 (GAVI) 承諾投入 2.5 億美元，用於改善低收入國家的疫苗可及性。

區域展望

北美 - 2024 年 6.2 億美元

北美在全球市場中處於領先地位，這得益於其較高的疫苗接種覆蓋率和不斷上升的疾病發病率。光是在美國，2016 年至 2020 年間就記錄了 44,660 起疫情，推動了疫苗需求。

亞太地區

這是第二大市場，也是預期複合年增長率最高的地區。例如，預計印度在 2024 年上半年將報告超過 6,000 例病例，這將推動疫苗的快速普及。

歐洲

強而有力的政府主導的疫苗接種計劃和近期疫苗推廣措施正在促進穩步增長。

拉丁美洲、中東/非洲

儘管市場佔有率較低，但不斷提高的公眾意識和有針對性的健康宣傳活動正在推動疫苗的逐步普及。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要國家和地區甲型肝炎流行情況（2024 年）
  • 主要公司產品線分析
  • 市場技術進步
  • 主要公司新產品發布
  • 主要產業趨勢（併購、合作等）

第五章：全球甲型肝炎疫苗市場分析、洞察與預測 (2019-2032)

  • 按類型劃分的市場分析、洞察與預測
    • 滅活​​疫苗
    • 減毒活疫苗
    • 其他
  • 按年齡組別劃分的市場分析、洞察與預測
    • 兒童
    • 成人
  • 按劑型劃分的市場分析、洞察與預測
    • 溶液
    • 凍乾粉
  • 依分銷管道劃分的市場分析、洞察與預測
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 按地區劃分的市場分析、洞察與預測
    • 北部美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美甲型肝炎疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲甲型肝炎疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章 亞太地區甲型肝炎疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲甲型肝炎疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲甲型肝炎疫苗市場分析、洞察與預測（2019-2032）

  • 依國家/地區
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析 (2024)
  • 公司簡介
    • 葛蘭素史克 (GSK plc)
    • 賽諾菲 (Sanofi)
    • 默克公司 (Merck & Co., Inc.)
    • 沃克哈特 (Wockhardt)
    • 印度免疫學有限公司 (Indian Immunologicals Ltd (IIL))
    • 中國生物技術有限公司 (SINOVAC)
    • Vaxines Trading, Inc.
    • 寶靈生物製藥株式會社 (Boryung Biopharma Co.)
Product Code: FBI113584

Growth Factors of hepatitis A vaccines Market

The global hepatitis A vaccines market is witnessing strong growth due to rising disease prevalence, expanding immunization programs, and increasing government initiatives aimed at preventing hepatitis A infections. According to the report, the market size reached USD 1.24 billion in 2024, is expected to grow to USD 1.26 billion in 2025, and is projected to rise significantly to USD 2.57 billion by 2032, registering a robust CAGR of 10.7% during the forecast period. With a 50% market share in 2024, North America remained the dominant region, reflecting advanced healthcare systems and strong adoption of immunization practices.

Hepatitis A is a viral liver infection transmitted primarily through contaminated food and water or via close personal contact. Symptoms range from fever, nausea, and abdominal discomfort to jaundice and acute liver failure. The infection is particularly prevalent in low- and middle-income regions due to insufficient sanitation, poor hygiene, and restricted access to clean water. As vaccination is the most effective preventive measure, demand for hepatitis A vaccines continues to grow worldwide. Leading companies such as GSK plc, Sanofi, Merck & Co., Inc., and SINOVAC offer globally approved vaccines, contributing to increasing immunization coverage.

Market Drivers

Growing Prevalence of Hepatitis A

Rising hepatitis A cases globally are driving vaccine uptake. Poor sanitation, contaminated water sources, and limited hygiene practices continue to be major risk factors. In Uzbekistan, for example, 9,507 hepatitis A infections among children were reported in the first two months of 2024, highlighting the urgent need for vaccination programs in high-risk regions.

Increased Government Immunization Initiatives

Governments worldwide are expanding national vaccination programs to prevent outbreaks and minimize healthcare expenditures. In the EU/EEA, 4,548 cases were reported in 2022, prompting authorities to reinforce vaccination strategies.

Market Restraints

High Vaccine Costs and Limited Access

Production of hepatitis A vaccines requires cold-chain logistics and stringent regulatory compliance, elevating overall costs. This restricts access in low-income countries. In Mexico, the cost per dose is USD 935.7, and full immunization requires two doses-making the vaccine unaffordable for many. This affordability gap continues to hinder global eradication efforts.

Market Opportunities

Indigenous Vaccine Development in Emerging Markets

Countries such as India and China are investing in domestic vaccine development to reduce reliance on imports. In January 2024, Indian Immunologicals Ltd launched Havisure, India's first indigenously developed hepatitis A vaccine, significantly improving accessibility and affordability. Such regional innovations are expected to create substantial market opportunities through 2032.

Market Challenges

Cold-Chain Inefficiencies

Hepatitis A vaccines must be stored between 2°C and 8°C. Many lower-income regions lack adequate cold-chain infrastructure, resulting in vaccine wastage and reduced immunization coverage. These limitations remain a key barrier to market expansion.

Market Trends

Rising Demand for Traveler Immunization

With global travel increasing, the demand for hepatitis A vaccination among travelers has grown significantly. Travel clinics and pharmacies in high-income countries report strong vaccine uptake as travelers visit hepatitis A-endemic nations. South Korea, for example, strongly recommends at least one dose before travel to at-risk regions.

Segmentation Overview

By Type

The inactivated vaccine segment dominated the market in 2024 due to global approvals and wide availability. In 2023, SINOVAC's inactivated vaccine Healive gained regulatory approval in Kyrgyzstan. Live attenuated vaccines, though effective, remain regionally concentrated in India and China.

By Age Group

The pediatric segment led the market due to established vaccination protocols. The U.S. CDC recommends routine vaccination for all children aged 12-23 months.

By Form

Solution-based vaccines such as Vaqta (Merck) and Havrix (GSK) hold the majority share due to ease of administration. Lyophilized powders remain important for extended shelf life and storage benefits.

By Distribution Channel

Government suppliers dominated in 2024, driven by large-scale procurement programs. In 2025, GAVI allocated USD 250 million to enhance vaccine access in low-income countries.

Regional Outlook

North America - USD 0.62 Billion in 2024

North America led the global market, supported by high vaccination rates and rising disease incidence. The U.S. alone recorded 44,660 outbreak cases between 2016 and 2020, fueling vaccine demand.

Asia Pacific

Second-largest market with the highest projected CAGR. India, for instance, reported over 6,000 cases in the first half of 2024, prompting rapid vaccine adoption.

Europe

Strong government immunization programs and recent vaccine initiatives contribute to steady growth.

Latin America & Middle East/Africa

Despite lower market shares, rising awareness and targeted health campaigns support gradual adoption.

Conclusion

With the market valued at USD 1.24 billion in 2024, expected to reach USD 1.26 billion in 2025, and projected to attain USD 2.57 billion by 2032, the global hepatitis A vaccines market is positioned for substantial long-term expansion. Increasing disease burden, rising vaccination initiatives, and new indigenous vaccine developments will collectively drive growth throughout the forecast period.

Segmentation By Type

  • Inactivated
  • Live Attenuated
  • Others

By Age Group

  • Pediatric
  • Adults

By Form

  • Solution
  • Lyophilized Powder

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Age Group, Dose, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Hepatitis A - by Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Technological Advancements in Market
  • 4.4. New Product Launches, by Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Inactivated
    • 5.1.2. Live Attenuated
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Age Group
    • 5.2.1. Pediatric
    • 5.2.2. Adolts
  • 5.3. Market Analysis, Insights and Forecast - By Form
    • 5.3.1. Solution
    • 5.3.2. Lyophilized Powder
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Inactivated
    • 6.1.2. Live Attenuated
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Age Group
    • 6.2.1. Pediatric
    • 6.2.2. Adolts
  • 6.3. Market Analysis, Insights and Forecast - By Form
    • 6.3.1. Solution
    • 6.3.2. Lyophilized Powder
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. S.
    • 6.5.2. Canada

7. Europe Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Inactivated
    • 7.1.2. Live Attenuated
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Age Group
    • 7.2.1. Pediatric
    • 7.2.2. Adolts
  • 7.3. Market Analysis, Insights and Forecast - By Form
    • 7.3.1. Solution
    • 7.3.2. Lyophilized Powder
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Inactivated
    • 8.1.2. Live Attenuated
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Age Group
    • 8.2.1. Pediatric
    • 8.2.2. Adolts
  • 8.3. Market Analysis, Insights and Forecast - By Form
    • 8.3.1. Solution
    • 8.3.2. Lyophilized Powder
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Inactivated
    • 9.1.2. Live Attenuated
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Age Group
    • 9.2.1. Pediatric
    • 9.2.2. Adolts
  • 9.3. Market Analysis, Insights and Forecast - By Form
    • 9.3.1. Solution
    • 9.3.2. Lyophilized Powder
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Inactivated
    • 10.1.2. Live Attenuated
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Age Group
    • 10.2.1. Pediatric
    • 10.2.2. Adolts
  • 10.3. Market Analysis, Insights and Forecast - By Form
    • 10.3.1. Solution
    • 10.3.2. Lyophilized Powder
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Wockhardt
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Indian Immunologicals Ltd (IIL)
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. SINOVAC
      • 11.2.6.1. Overview
        • 11.2.6.1.1. Products & services
        • 11.2.6.1.2. SWOT Analysis
        • 11.2.6.1.3. Recent Developments
        • 11.2.6.1.4. Strategies
        • 11.2.6.1.5. Financials (Based on Availability)
    • 11.2.7. Vaxines Trading, Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Boryung Biopharma Co.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 2: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2033
  • Table 3: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2034
  • Table 4: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 5: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 7: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 8: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
  • Table 9: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 10: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 12: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 13: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
  • Table 14: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 15: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 17: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 18: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
  • Table 19: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 22: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 23: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
  • Table 24: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 25: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 26: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 27: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 28: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
  • Table 29: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Figure 1: Global Hepatitis A Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Hepatitis A Vaccines Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024 & 2032
  • Figure 4: Global Hepatitis A Vaccines Market Value Share (%), by Form 2024 & 2032
  • Figure 5: Global Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 6: Global Hepatitis A Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 7: North America Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 8: North America Hepatitis A Vaccines Market Value Share (%), by Type, 2024
  • Figure 9: North America Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 10: North America Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 11: North America Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
  • Figure 12: North America Hepatitis A Vaccines Market Value Share (%), by Form, 2024
  • Figure 13: North America Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 14: North America Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 15: North America Hepatitis A Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Hepatitis A Vaccines Market Value Share (%), By Country, 2024
  • Figure 17: Europe Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 18: Europe Hepatitis A Vaccines Market Value Share (%), by Type, 2024
  • Figure 19: Europe Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 20: Europe Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 21: Europe Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
  • Figure 22: Europe Hepatitis A Vaccines Market Value Share (%), by Form, 2024
  • Figure 23: Europe Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 24: Europe Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 25: Europe Hepatitis A Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Hepatitis A Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 28: Asia Pacific Hepatitis A Vaccines Market Value Share (%), by Type, 2024
  • Figure 29: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 30: Asia Pacific Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 31: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
  • Figure 32: Asia Pacific Hepatitis A Vaccines Market Value Share (%), by Form, 2024
  • Figure 33: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 35: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Hepatitis A Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 38: Latin America Hepatitis A Vaccines Market Value Share (%), by Type, 2024
  • Figure 39: Latin America Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 40: Latin America Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 41: Latin America Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
  • Figure 42: Latin America Hepatitis A Vaccines Market Value Share (%), by Form, 2024
  • Figure 43: Latin America Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 45: Latin America Hepatitis A Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Hepatitis A Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 48: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), by Type, 2024
  • Figure 49: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 50: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 51: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
  • Figure 52: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), by Form, 2024
  • Figure 53: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 55: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 57: Global Hepatitis A Vaccines Market Share (%), By Company, 2024